Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis.

TitleVisceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis.
Publication TypeJournal Article
Year of Publication2004
AuthorsFernandez-Guerrero ML, Robles P, Rivas P, Mojer F, Muniz G, de Gorgolas M
JournalActa tropica//Acta Trop
Volume90
Issue1
Pagination11 - 6
Date Published2004
ISBN Number0001-706X
Other Numbers23a, 0370374
Keywords*HIV Infections/im [Immunology], *HIV Seronegativity/im [Immunology], *Immunocompromised Host/im [Immunology], *Leishmaniasis, Visceral/pp [Physiopathology], Adolescent, Adult, Aged, Female, Humans, Leishmaniasis, Visceral/co [Complications], Leishmaniasis, Visceral/mo [Mortality], Male, Medical Records, Middle Aged, Prognosis, Retrospective Studies
Abstract

Visceral leishmaniasis is basically a disease of healthy infants and adults. However, in the last decade an increasing number of cases of kala azar in immunocompromised patients have been reported with emphasis on atypical manifestations of the disease. During a period of 11 years, 20 immunocompromised patients with AIDS (12 patient), haematological neoplasia (3 patients), corticosteroid therapy (3 patients) or renal transplantation (2 patients) were studied by one or more of the authors. We did not find differences in the presentation of leishmaniasis between patient with or without AIDS and most patients had fever, enlargement of the liver and spleen, blood cytopenias and biochemical abnormalities. Serology was more frequently positive in HIV-negative than in HIV-positive patients (100% versus 63.6%; P=0.13). Bone marrow biopsy was diagnostic in 66% and 87% of patients with and without AIDS, respectively. Failure of anti-leishmanial therapy occurred in 6 of 19 patients treated (31.5%), and 3 patients with AIDS and another 3 without AIDS died during the first episode of leishmaniasis. Of 12 survivors, relapses occurred in five (41.6%). Only patients in whom immunosuppression was ameliorated by means of antiretroviral therapy or by reduction of corticosteroid and other immunosuppressive drugs did not relapse. Treatment of kala azar in immunocompromised host is in satisfactory and new drugs or strategies are urgently needed.

Notify Library Reference ID4001

Related Incidents